Another study in NSCLC patients treated with anti-PD-1 antibody revealed that patients with a proportion score (percentages of neoplastic cells with membranous PD-L1 staining) of at least 50% had a higher response rate and longer progression-free/overall survival than those with a proportion score of less than 50% [15]. Here, CD274 is linked to non-small cell lung carcinoma.